Ā | Complete group (nā=ā182) | Cross-validation | |||||
---|---|---|---|---|---|---|---|
p Value | BH-corrected p value | Significant results (pā<ā0.05) | Median p values | ||||
Both sets | One set | Neither set | Set 1 | Set 2 | |||
Disease parameters | |||||||
āDisease duration | 0.061 | 0.25 | 0 | 371 | 629 | 0.18 | 0.20 |
āDAS28 | 0.18 | 0.41 | 0 | 199 | 801 | 0.38 | 0.32 |
āTJC28 | 0.10 | 0.36 | 0 | 264 | 736 | 0.25 | 0.25 |
āSJC28 | 0.61 | 0.76 | 1 | 39 | 960 | 0.53 | 0.59 |
āVAS | 0.21 | 0.44 | 0 | 122 | 878 | 0.39 | 0.35 |
āErosions | 0.41 | 0.60 | 0 | 61 | 939 | 0.50 | 0.51 |
āNodules | 0.24 | 0.46 | 1 | 143 | 856 | 0.39 | 0.41 |
Laboratory parameters | |||||||
āESR | 0.86 | 0.98 | 6 | 18 | 976 | 0.60 | 0.58 |
āESR dichotomous (>20) | 0.71 | 0.85 | 0 | 19 | 981 | 0.60 | 0.58 |
āCRP | 0.14 | 0.39 | 0 | 233 | 767 | 0.30 | 0.29 |
āCRP dichotomous (ā„10) | 0.15 | 0.38 | 0 | 190 | 810 | 0.30 | 0.33 |
āRF titer | 0.36 | 0.60 | 1 | 66 | 933 | 0.46 | 0.50 |
āRF positivity | 0.96 | 1.0 | 3 | 3 | 994 | 0.62 | 0.61 |
āACPA titer | 0.38 | 0.59 | 0 | 64 | 936 | 0.47 | 0.51 |
āACPA positivity | 0.86 | 0.98 | 1 | 9 | 990 | 0.64 | 0.64 |
āACPA high positivity (ā„3Ć cutoff) | 0.29 | 0.52 | 0 | 79 | 921 | 0.44 | 0.44 |
āRF- and ACPA-positive vs. rest | 0.57 | 0.79 | 0 | 34 | 966 | 0.59 | 0.58 |
āRF- and ACPA-negative vs. rest | 0.13 | 0.41 | 0 | 219 | 781 | 0.27 | 0.28 |
Medication parameters | |||||||
āMTX use | Ā | Ā | 2 | 3 | 995 | 0.66 | 0.65 |
āMTX dosage | 0.57 | 0.79 | 1 | 29 | 970 | 0.58 | 0.58 |
āPrednisone use | 0.037 | 0.19 | 0 | 526 | 474 | 0.14 | 0.14 |
āPrednisone dosage | 0.017 | 0.14 | 0 | 718 | 282 | 0.092 | 0.090 |
āHCQ use | 0.001 | 0.013 | 521 | 479 | 0 | 0.015 | 0.015 |
āSSZ use | 0.023 | 0.14 | 0 | 584 | 416 | 0.11 | 0.11 |
āPREDN and/or HCQ and/or SSZ use | 0.00032 | 0.0080 | 612 | 388 | 0 | 0.012 | 0.010 |